InflaRx (IFRX)
(Real Time Quote from BATS)
$1.63 USD
-0.10 (-5.78%)
Updated Jul 3, 2024 02:30 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IFRX 1.63 -0.10(-5.78%)
Will IFRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
Other News for IFRX
InflaRx Announces $75M Share Sales Agreement
Buy Rating for InflaRx: Gohibic’s Market Potential and BARDA’s Phase 2 Endorsement
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
Barda selects InflaRx's GOHIBIC for clinical trial to evaluate ARDS therapeutic
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial